Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence

Stefanie R. Bailey1,2,3, Michelle H. Nelson1,2,3,7, Kinga Majchrzak1,2,3,8, Jacob S. Bowers1,2,3, Megan M. Wyatt1,2,3, Aubrey S. Smith1,2,3, Lillian R. Neal1,2,3, Keisuke Shirai4,9, Carmine Carpenito5,10, Carl H. June5, Michael J. Zilliox6 & Chrystal M. Paulos1,2,3 1Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USA. 2Department of Surgery, Medical University of South Carolina, Charleston, SC 29425, USA. 3Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston, SC 29425, USA. 4Hematology/Oncology Division, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA. 5Department of Pathology and Laboratory Medicine, University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA. 6Department of Public Health Sciences, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA. 7Aptevo Therapeutics, Seattle, WA 98121, USA. 8Present address: Department of Physiological Sciences, Faculty of Veterinary Medicine, Warsaw University of Life Sciences, Warsaw, 02-787, Poland. 9Department of Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH 02714, USA. 10Present address: Eli Lilly and Company, New York, NY 10016, USA.